バンコマイシン耐性黄色ブドウ球菌（VRSA）感染症とは、黄色ブドウ球菌という細菌が抗生物質バンコマイシンに対する薬剤耐性を獲得することにより発症する疾患です。主なリスク要因には、強力な抗生物質を不適切な方法で摂取することにより細菌が抗生物質への耐性を強めることや、免疫系の弱体化、長期間の入院生活などが含まれています。主な症状として、高熱や悪寒、せき、胸痛、呼吸困難、頻脈などが挙げられます。
目次
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved in Therapeutics Development
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drug Profiles
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Amprologix Ltd, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics Inc, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Destiny Pharma Plc, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Lysimmune BioScience, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Roivant Sciences Ltd, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Sano Chemicals Inc, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TGV-Inhalonix Inc, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Ltd, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, 2021
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, 2021
List of Figures
Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
